What is the immediate management for a 30‑year‑old woman with suspected thrombotic thrombocytopenic purpura presenting with abrupt chest discomfort, severe thrombocytopenia (~40 × 10⁹/L), normal troponin I, and rapid progression to cardiac arrest?

Immediate Management of Suspected TTP with Cardiac Arrest

In a 30-year-old woman with suspected TTP presenting with chest discomfort, severe thrombocytopenia (~40 × 10⁹/L), and rapid progression to cardiac arrest, you must immediately initiate therapeutic plasma exchange (TPE) within 4-8 hours of suspected diagnosis, start high-dose corticosteroids, and provide ICU-level continuous cardiac monitoring—treatment cannot wait for ADAMTS13 confirmation given the life-threatening presentation with cardiac involvement. 1

Critical First Steps

Immediate Resuscitation and Stabilization

• Cardiac arrest management: Standard ACLS protocols while recognizing that cardiac microthrombi are the likely underlying cause 1, 2
• Do NOT transfuse platelets despite severe thrombocytopenia—platelet transfusion can worsen microvascular thrombosis in TTP 1
• ICU admission is mandatory even after stabilization, as TTP patients have ongoing risk of cardiac arrest from cardiac microthrombi, arrhythmias, and cardiogenic shock 1

Diagnostic Workup (While Initiating Treatment)

• Send ADAMTS13 activity and inhibitor levels immediately, but do not wait for results to start treatment 1
• The normal troponin I is reassuring but does not exclude cardiac microthrombosis—troponin can be falsely reassuring in TTP and may be cleared rapidly by plasmapheresis 3
• Confirm microangiopathic hemolytic anemia: peripheral smear for schistocytes, elevated LDH, low hemoglobin, elevated indirect bilirubin 4
• Important caveat: Absence of schistocytes does NOT rule out TTP—up to 10% of cases may lack schistocytes initially 4

Definitive Treatment Algorithm

1. Therapeutic Plasma Exchange (TPE) - Cornerstone Therapy

TPE must be initiated within 4-8 hours of suspected diagnosis 1

• Volume: 1-1.5 plasma volumes daily 1
• Replacement fluid: Fresh frozen plasma, cryosupernatant, or solvent-detergent treated plasma 1
• Central line placement: Use ultrasound guidance with prolonged compression despite thrombocytopenia—do NOT give platelets for line placement 1
• Duration: Continue daily until platelet count >150 × 10⁹/L for at least 24 hours 1
• Mortality impact: Delaying TPE increases mortality, irreversible organ damage, and healthcare costs 1

2. Corticosteroid Therapy - Start Immediately

High-dose methylprednisolone is appropriate in severe cases like this 1

• Standard dosing: Prednisolone/prednisone 1 mg/kg/day for first 3 days 1
• In severe presentations with cardiac involvement: Consider higher doses of methylprednisolone 1
• Corticosteroid pulse therapy is an independent predictor of clinical response 5

3. Rituximab - Initiate Upon ADAMTS13 Confirmation

Start rituximab immediately once severe ADAMTS13 deficiency (<10%) is confirmed and hepatitis B is excluded 1

• Dosing: 375 mg/m² weekly for 4 weeks (or every 3-4 days during TPE to compensate for increased clearance) 1
• Benefits:
  • Expedites platelet recovery and decreases TPE sessions needed 1
  • Reduces relapse risk for at least 12 months 1
  • Number-needed-to-treat to prevent one relapse: 3.3 patients 1
• Hepatitis B screening mandatory: Check serology and nucleic acid testing; provide prophylactic antivirals if past infection detected 1

4. Caplacizumab - Consider for Severe Cases

Caplacizumab should ideally be initiated upon confirmation of severe ADAMTS13 deficiency, but early empiric use may be considered in highly suggestive severe cases 1

• Dosing: 10 mg/day (IV initially, then subcutaneous) until ADAMTS13 recovery 1
• Evidence: Improves survival, decreases organ damage markers, reduces TPE needs and exacerbations 1
• Number-needed-to-treat: 35 to prevent one death 1
• Main adverse effect: Bleeding (rarely severe; manageable with VWF concentrate) 1

Critical Pitfalls in This Case

Cardiac Complications Require Special Attention

• Cardiac arrest in TTP is caused by cardiac microthrombosis 1, 2
• Continuous cardiac monitoring is essential throughout acute phase 1
• A case report documented sudden cardiac death on day 9 despite treatment, with autopsy showing microvascular platelet thrombi in multiple organs including heart 2
• Troponin interpretation is complicated: Plasmapheresis rapidly clears troponin, potentially providing false reassurance about cardiac injury 3

Age and Severity Predict Mortality

Independent predictors of mortality in this patient include:

• Age >45 years (this patient is 30, favorable) 5
• Pentad symptoms (thrombocytopenia, hemolytic anemia, neurologic symptoms, renal dysfunction, fever) 5
• LDH >1500 U/L 5
• Cardiac involvement with arrest represents severe disease

Treatment Cannot Be Delayed

• Mortality without treatment: >90% 4
• Mortality with prompt treatment: 10-20% 4
• Only 30% of patients are diagnosed at hospitals where TPE is available—immediate transfer is critical if TPE unavailable 1
• If TPE unavailable, use plasma infusions as bridge until transfer 1

Monitoring and Response Definitions

Clinical Response

• Platelet count recovery to >150 × 10⁹/L 1
• LDH <1.5 times upper limit of normal 1
• No new evidence of organ damage 1

Exacerbation vs. Remission

• Exacerbation: Platelet count falls to <150 × 10⁹/L within 30 days of stopping TPE or caplacizumab 1
• Clinical remission: Clinical response persisting ≥30 days without TPE and anti-VWF therapy 1

Ongoing Cardiac Monitoring

Given the cardiac arrest presentation, this patient requires:

• Continuous telemetry throughout acute phase
• Serial cardiac biomarkers (recognizing plasmapheresis effects on interpretation)
• Echocardiography to assess for cardiomyopathy or wall motion abnormalities
• Vigilance for arrhythmias and cardiogenic shock 1